Related Experiment Video

Updated: Sep 28, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone

Steven M Watkins1, Peter R Reifsnyder, Huei-ju Pan

  • 1Lipomics Technologies, Inc, 2545 Boatman Ave, West Sacramento, CA 95691, USA. steve.watkins@lipomics.com

Journal of Lipid Research
|October 29, 2002
PubMed

Insights

Rosiglitazone suppressed Type 2 diabetes in mice but caused liver issues. Comprehensive metabolomics revealed drug-induced metabolic disruptions across multiple tissues, highlighting the need for broader monitoring.

Area of Science:

  • Metabolomics
  • Endocrinology
  • Pharmacology

Background:

  • Therapies for chronic diseases must precisely target metabolic pathways without causing adverse effects.
  • Relying on limited biomarkers to assess drug efficacy can miss unintended metabolic consequences.

Purpose of the Study:

  • To investigate the effects of the PPARgamma agonist rosiglitazone on lipid metabolism in a mouse model of Type 2 diabetes.
  • To comprehensively assess rosiglitazone's impact on structural lipid metabolism using metabolomics.

Main Methods:

  • Utilized a comprehensive metabolomic assessment of lipid metabolites.
  • Administered rosiglitazone (200 mg/kg diet) to obese (NZO x NON)F1 male mice with Type 2 diabetes.
  • Analyzed tissue-specific and plasma lipid profiles.

Main Results:

  • Rosiglitazone suppressed Type 2 diabetes but exacerbated hepatic steatosis.
  • Metabolomic analysis revealed rosiglitazone-induced hypolipidemia, increased de novo fatty acid synthesis, and decreased peroxisomal lipid biosynthesis.
  • Significant alterations in cardiac free fatty acid and cardiolipin metabolism, and adipose polyunsaturated fatty acid accumulation were observed.

Conclusions:

  • Rosiglitazone's phenotypic effects are mediated by multiple, tissue-specific metabolic alterations.
  • Plasma lipid metabolomics can serve as a valuable tool for assessing drug responses in clinical settings.
  • Comprehensive metabolomic profiling is crucial for understanding drug-induced metabolic changes and preventing adverse effects.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...